Anne-Sophie de Faucigny

Public Communications Contact presso GETLINK SE

Health Technology

Transportation

Consumer Services

Profilo

Anne-Sophie de Faucigny is currently the Group Chief Communication Officer at Getlink SE.
Previously, she worked as the Director at Yposkesi from 2018 to 2021.
She is a graduate of Institut d’Études Politiques de Toulouse.

Posizioni attive di Anne-Sophie de Faucigny

Società	Posizione	Inizio
GETLINK SE	Public Communications Contact	01/10/2022

Tutte le posizioni attive di Anne-Sophie de Faucigny

Precedenti posizioni note di Anne-Sophie de Faucigny

Società	Posizione	Fine
Yposkesi Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021.	Direttore/Membro del Consiglio	01/01/2021

Vedi nel dettaglio l'esperienza di Anne-Sophie de Faucigny

Formazione di Anne-Sophie de Faucigny

Institut d’Études Politiques de Toulouse

Graduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Anne-Sophie de Faucigny

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
GETLINK SE	Transportation

Aziende private	1
Yposkesi Yposkesi BiotechnologyHealth Technology Part of SK, Inc., Yposkesi is a French-based CDMO that offers bioprocess development and CGMP manufacturing services for AAV and lentiviral vector production. The company is based in Corbeil-Essonnes, France. The French company provides support for gene therapy and aims to provide the best and most complete viral vector solutions. Yposkesi provides flexibility to develop the best process for cell and gene therapy production and process for viral vector. The company was founded in 2015, and Alain Lamproye has been the CEO of the company since 2017. Yposkesi was acquired by SK Pharmteco, Inc. on March 31, 2021.	Health Technology